Safety and efficacy of HIV Pre-Exposure Prophylaxis (PrEP): an overview of systematic reviews
DOI:
https://doi.org/10.33448/rsd-v11i6.29336Keywords:
Pre-Exposure Prophylaxis (PrEP); HIV; Health teaching.Abstract
The present study carried out a survey of the safety and efficacy profile of HIV Pre-Exposure Prophylaxis, through an overview of systematic reviews. The bibliographic search was carried out with data published until September 10, 2021, in PubMed, Scopus Elsevier, SciELO and Cochrane databases, according to the PRISMA and Cochrane recommendations. After the identification, screening and eligibility steps, performed by two independent reviewers, six articles met the requirements and were included in the final synthesis. Data demonstrated that all PrEP regimens significantly reduced the risk of acquiring HIV compared to placebo and non-PrEP users, with efficacy dependent on adherence profile, reaching a 96% reduction in infection risk. Adverse events were similar between the PrEP and placebo/non-PrEP groups. Cases of drug-resistant HIV infection occurred among PrEP users who started therapy when they were acutely infected, but the incidence of acquiring drug-resistant HIV while using PrEP was low. Furthermore, there was no association between PrEP use and changes in risky sexual behavior. Thus, it is possible to conclude that this therapy presented a good safety and efficacy profile, thus, the promotion of actions that contribute to its expansion as a public health promotion policy, can reduce the number of new HIV infections and improve the quality of life of individuals at high risk of acquiring this virus.
References
Brasil. Ministério da Saúde. (2011). Guia para Notificação de Reações Adversas em Oncologia. Brasília: Ministério da Saúde.
Brasil. Ministério da Saúde. (2013). Portaria Nº 29, de 17 de dezembro de 2013: aprova o Manual Técnico para o Diagnóstico da Infecção pelo HIV em Adultos e Crianças e dá outras providências. Brasília: Ministério da Saúde.
Brasil. Ministério da Saúde. (2017a). Departamento de Doenças Crônicas e Infecções Sexualmente Transmissíveis. Prevenção Combinada do HIV. http://www.aids.gov.br/pt-br/publico-geral/previna-se.
Brasil. Ministério da Saúde. (2018a). Secretaria de Vigilância em Saúde. Manual Técnico para o Diagnóstico da Infecção pelo HIV em Adultos e Crianças. Brasília: Ministério da Saúde.
Brasil. Ministério da Saúde. (2018b). Comissão Nacional de Incorporação de Tecnologias no SUS. Tenofovir associado a entricitabina (TDF/FTC 300/200mg) como profilaxia pré-exposição (PrEP) para populações sob maior risco de adquirir o vírus da imunodeficiência humana (HIV). Brasília: Ministério da Saúde.
Brasil. Ministério da Saúde. (2018b). Secretaria de Vigilância em Saúde. Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Adultos. Brasília: Ministério da Saúde.
Brasil. Ministério da Saúde. (2020). Boletim epidemiológico de HIV e Aids 2020. Brasília: Ministério da Saúde.
Brasil. Ministério da Saúde. (2021). Resolução RDC Nº 548, de 30 de agosto de 202: Dispõe sobre a realização de ensaios clínicos com dispositivos médicos no Brasil. Brasília: Ministério da Saúde.
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., & Bangkok Tenofovir Study Group. (2013). Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 381(9883), 2083-2090.
Chou, R., Evans, C., Hoverman, A., Sun, C., Dana, T., Bougatsos, C., & Korthuis, P. T. (2019). Pre-exposure prophylaxis for the prevention of HIV infection: a systematic review for the US Preventive Services Task Force.
Fonner, V. A., Dalglish, S. L., Kennedy, C. E., Baggaley, R., O’reilly, K. R., Koechlin, F. M., & Grant, R. M. (2016). Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (London, England), 30(12), 1973.
Galvão, T. F., & Pereira, M. G. (2014). Revisões sistemáticas da literatura: passos para sua elaboração. Epidemiologia e Serviços de Saúde, 23, 183-184.
Higgins, J. P., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (Eds.). (2019). Cochrane handbook for systematic reviews of interventions. John Wiley & Sons.
Huang, X., Hou, J., Song, A., Liu, X., Yang, X., Xu, J., & Wu, H. (2018). Efficacy and safety of oral TDF-based pre-exposure prophylaxis for men who have sex with men: A systematic review and meta-analysis. Frontiers in pharmacology, 9, 799.
Joseph Davey, D. L., Pintye, J., Baeten, J. M., Aldrovandi, G., Baggaley, R., Bekker, L. G., & PrEP in Pregnancy Working Group. (2020). Emerging evidence from a systematic review of safety of pre‐exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?. Journal of the International AIDS Society, 23(1), e25426.
McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., & Gill, O. N. (2016). Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet, 387(10013), 53-60.
Melo, B. P., Pedro, R. E., Guariglia, D. A., Peres, S. B., & Moraes, S. M. F. D. (2017). Respostas agudas do exercício físico em pessoas infectadas pelo HIV: uma revisão sistemática. Revista Brasileira de Medicina do Esporte, 23, 152-159.
Mulligan, K., Glidden, D. V., Anderson, P. L., Liu, A., McMahan, V., Gonzales, P., & Rooney, J. (2015). Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clinical infectious diseases, 61(4), 572-580.
Murewanhema, G., Malisheni, M., & Takah, N. F. (2021). The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review. The Pan African Medical Journal, 38.
Okwundu, C. I., Uthman, O. A., & Okoromah, C. A. (2012). Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals. Cochrane database of systematic reviews, (7).
Portela Nunes, E. (2016). Terapia antirretroviral e função renal. The Brazilian Journal of Infectious Diseases, 2(3), 82-90.
Redmond, A. M., & McNamara, J. F. (2015). The road to eliminate mother-to-child HIV transmission. Jornal de pediatria, 91, 509-511.
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., & Henry, D. A. (2017). AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. The bmj, 358.
Singhroy, D. N., Wainberg, M. A., & Mesplède, T. (2015). Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity. Antimicrobial Agents and Chemotherapy, 59(5), 2882-2885.
Sun, H., Kim, D., Li, X., Kiselinova, M., Ouyang, Z., Vandekerckhove, L., & Lichterfeld, M. (2015). Th1/17 polarization of CD4 T cells supports HIV-1 persistence during antiretroviral therapy. Journal of virology, 89(22), 11284-11293.
Underhill, K. (2013). Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: balancing methodological rigor and research ethics. Social science & medicine, 94, 115-123.
United Nations Programme on HIV/Aids (UNAIDS). (2021). Estatísticas: Estatísticas globais sobre HIV 2021. https://unaids.org.br/
Volk, J. E., Marcus, J. L., Phengrasamy, T., Blechinger, D., Nguyen, D. P., Follansbee, S., & Hare, C. B. (2015). No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clinical infectious diseases, 61(10), 1601-1603.
World Health Organization. (2017). HIV drug resistance report 2017. Recuperado de https://apps.who.int/iris/handle/10665/255896
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Luís Eduardo Oliveira da Silva; Jadon Araújo Macêdo Silva; Ywkiane Lopes de Araújo; Igor Gabriel da Silva Ramalho; Adriano Francisco Alves
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
